| Jison Hong, MD | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Jison Hong |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 16 Years |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740441823 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | A119003 (California) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | A119003 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| St Joseph Hospital | Eureka, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
News Archive
New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).
A new study led by researchers in the Louisiana State University Superfund Research Program demonstrates that children who are exposed to a certain type of environmental air pollution are more likely to contract community acquired pneumonia, or CAP, and to be hospitalized for longer periods of time.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.
Diffuse cerebral atrophy in patients with anti-N-methyl-D-aspartate receptor encephalitis does not necessarily mean irreversible brain damage, whereas progressive cerebellar atrophy may indicate a poor long-term prognosis, researchers report.
The Avicena Group has announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to HD-02, the company's proprietary drug candidate for the treatment of Huntington's disease.
› Verified 9 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).
A new study led by researchers in the Louisiana State University Superfund Research Program demonstrates that children who are exposed to a certain type of environmental air pollution are more likely to contract community acquired pneumonia, or CAP, and to be hospitalized for longer periods of time.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.
Diffuse cerebral atrophy in patients with anti-N-methyl-D-aspartate receptor encephalitis does not necessarily mean irreversible brain damage, whereas progressive cerebellar atrophy may indicate a poor long-term prognosis, researchers report.
The Avicena Group has announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to HD-02, the company's proprietary drug candidate for the treatment of Huntington's disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jison Hong, MD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 | Jison Hong, MD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 |
News Archive
New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).
A new study led by researchers in the Louisiana State University Superfund Research Program demonstrates that children who are exposed to a certain type of environmental air pollution are more likely to contract community acquired pneumonia, or CAP, and to be hospitalized for longer periods of time.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.
Diffuse cerebral atrophy in patients with anti-N-methyl-D-aspartate receptor encephalitis does not necessarily mean irreversible brain damage, whereas progressive cerebellar atrophy may indicate a poor long-term prognosis, researchers report.
The Avicena Group has announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to HD-02, the company's proprietary drug candidate for the treatment of Huntington's disease.
› Verified 9 days ago
Prista Charuworn, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 300 Pasteur Dr, Alway Build M211, Mc 5187, Stanford, CA 94305 Phone: 650-723-6661 | |
Yu Kuang Lai, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Andrea Lorenze, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Drive, Lane 154, Stanford, CA 94305 Phone: 650-723-6661 Fax: 650-498-6205 | |
Audra Horomanski, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 Fax: 650-498-6205 | |
Meghan Brady Marmor, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Lauren Michelle Ulsh, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Ann M Chen, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, A149, Mc5202, Stanford, CA 94305 Phone: 650-725-3376 Fax: 650-723-8305 |